

1 **Epigenetic profiling of Italian patients identified methylation sites associated with**  
2 **hereditary Transthyretin amyloidosis**

3 Antonella De Lillo,<sup>1</sup> Gita A. Pathak,<sup>2,3</sup> Flavio De Angelis,<sup>1,2,3</sup> Marco Di Girolamo,<sup>4</sup> Marco Luigetti,<sup>5,6</sup>  
4 Mario Sabatelli,<sup>6,7</sup> Federico Perfetto,<sup>8</sup> Sabrina Frusconi,<sup>9</sup> Dario Manfredotto,<sup>4</sup> Maria Fuciarelli,<sup>1</sup> Renato  
5 Polimanti<sup>2,3\*</sup>

6  
7 <sup>1</sup>Department of Biology, University of Rome Tor Vergata, Rome, Italy

8 <sup>2</sup>Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA

9 <sup>3</sup>VA CT Healthcare Center, West Haven, CT, USA

10 <sup>4</sup>Clinical Pathophysiology Center, Fatebenefratelli Foundation – ‘San Giovanni Calibita’ Fatebenefratelli  
11 Hospital, Rome, Italy

12 <sup>5</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, Rome, Italy

13 <sup>6</sup>Università Cattolica del Sacro Cuore, Rome, Italy

14 <sup>7</sup>‘Centro Clinico NEMO adulti’, Rome, Italy

15 <sup>8</sup>Regional Amyloid Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

16 <sup>9</sup>Genetic Diagnostics Unit, Laboratory Department, Careggi University Hospital, Florence, Italy

17

18 \*Corresponding author:

19 Dr. Renato Polimanti. Department of Psychiatry, Yale University School of Medicine and VA CT

20 Healthcare Center, VA CT 116A2, 950 Campbell Avenue, West Haven,

21 CT 06516, USA. Tel: +1 203 932 5711 x5745; Fax: +1 203 937-3897; E-mail:

22 renato.polimanti@yale.edu; ORCID: 0000-0003-0745-6046

23

24

## 25 **Abstract**

26 Hereditary Transthyretin (TTR) Amyloidosis (hATTR) is a rare life-threatening disorder caused by  
27 amyloidogenic coding mutations located in *TTR* gene. To understand the high phenotypic variability  
28 observed among carriers of *TTR* disease-causing mutations, we conducted an epigenome-wide association  
29 study (EWAS) assessing more than 700,000 methylation sites and testing i) *TTR* coding mutation carriers  
30 vs. non-carriers, and ii) Val30Met (rs28933979) carriers vs. carriers of other *TTR* mutations. In the first  
31 analysis, we observed a significant methylation change at cg09097335 site located in *Beta-secretase 2*  
32 (*BACE2*) gene (beta =-0.60, p=6.26×10<sup>-8</sup>). This gene is involved in a protein interaction network enriched  
33 for biological processes and molecular pathways related to amyloid-beta metabolism (Gene  
34 Ontology:0050435, q=0.007), amyloid fiber formation (Reactome HSA-977225, q=0.008), and  
35 Alzheimer's disease (KEGG hsa05010, q=2.2×10<sup>-4</sup>). Additionally, *TTR* and *BACE2* share APP (Amyloid-  
36 beta precursor protein) as a validated protein interactor. In the second analysis, we observed that  
37 Val30Met carriers have a significant hypomethylation at cg13139646 site located in *TTR* exonic region  
38 (beta=-2.18, p=3.34×10<sup>-11</sup>). A methylation quantitative trait locus analysis considering a 20 Kb region  
39 including *TTR* coding and non-coding regions suggested that *TTR* coding variants (Ile68Leu,  
40 rs121918085; Ala120Ser, rs876658108; Gly6Ser, rs1800458) have independent effects on cg13139646  
41 methylation, while no independent effect was observed for non-coding variants. In conclusion, we  
42 provide novel insights related to the molecular mechanisms involved in the complex heterogeneity of  
43 hATTR, highlighting the role of epigenetic regulation in this rare disorder.

44

## 45 **Key words**

46 hATTR, amyloidosis, Val30Met mutation, epigenetics, methylation, mQTL, modifier gene.

47

## 48 **Background**

49 Hereditary transthyretin amyloidosis (OMIM#105210) (hATTR) is a life-threatening disorder caused by  
50 transthyretin (TTR) misfolding and consequently amyloid fibril deposition in several tissues (e.g.,  
51 peripheral nerves, heart, and gastrointestinal tract) (1, 2). This rare condition is characterized by extreme  
52 clinical heterogeneity including age of onset, penetrance, and clinical display (3-5). To date, more than  
53 130 amyloidogenic mutations have been identified in the coding regions of the *TTR* gene, which are the  
54 cause of hATTR (6). The prevalence of hATTR is estimated to be approximately 1/100,000 (7). However,  
55 endemic areas of hATTR were identified in Portugal and Sweden (4, 5). Although both of these regions  
56 are affected by the same amyloidogenic mutation, Val30Met (rs28933979), their penetrance and age of  
57 onset are different: early age of onset and high penetrance in Portugal (4, 5, 8, 9); late age of onset and  
58 low penetrance in Sweden and in non-endemic countries (3, 10, 11). It has been hypothesized that  
59 hATTR phenotypic heterogeneity is due to the contribution of genetic and non-genetic factors involved in  
60 the complex genotype-phenotype correlation observed (12-18). Recent data strongly support the role of  
61 non-coding regulatory variation on *TTR* gene expression, as one of the mechanisms affecting the  
62 phenotypic manifestations observed in carriers of *TTR* amyloidogenic mutations (19-22). Among  
63 genomic regulatory features, epigenetic modifications are demonstrated to be key mechanisms in  
64 modulating a wide range of molecular functions and potential targets to develop novel treatments (23-25).  
65 Of several epigenetic modifications, DNA methylation is the most studied with respect to human traits  
66 and diseases (23). With respect to monogenic disorders, methylation studies investigated the role of  
67 epigenetic changes involved in the phenotypic expression observed among carriers of disease-causing  
68 mutations (26-28). Although epigenetic modifications have the potential to be involved in hATTR  
69 pathogenic mechanisms, to our knowledge no study explored methylation changes of patients affected by  
70 this life-threatening disease. In the present study, we conducted an epigenome-wide association study  
71 (EWAS) to identify DNA methylation associated with hATTR, investigating 48 carriers of *TTR*  
72 amyloidogenic mutations and 32 controls. We also tested whether there are significant epigenetic changes  
73 among carriers of different amyloidogenic mutations. The results obtained showed: i) hATTR confirmed

74 cases have significant methylation changes in modifier genes potentially involved in amyloidogenic  
75 processes; ii) carriers of Val30Met mutation showed a significant hypomethylation in *TTR* gene when  
76 compared to the carriers of other *TTR* amyloidogenic mutations.

77

## 78 **Results**

79 The epigenome-wide analysis testing the differences between 48 carriers of *TTR* amyloidogenic  
80 mutations and 32 controls identified a significant methylation site surviving false discovery rate multiple  
81 testing correction (FDR  $q < 0.05$ ) at the cg09097335 site located in *Beta-secretase 2 (BACE2)* gene body  
82 ( $\beta = -0.60$ ,  $p = 6.26 \times 10^{-8}$ , FDR  $q = 0.044$ ; Table 1). Carriers of *TTR* amyloidogenic mutations showed a  
83 significant hypomethylation when compared to controls (Figure 1). To characterize the function of  
84 *BACE2* protein product, we investigated interactive proteins based on multiple experimental and  
85 computational evidence, identifying five candidates with medium-to-highest interaction confidence  
86 (Figure 2). These include FYN (FYN proto-oncogene, Src family tyrosine kinase; interaction  
87 score=0.809), BACE1 (Beta-secretase 1; interaction score=0.804), APP (amyloid-beta precursor protein;  
88 interaction score=0.430), IGHV3-11 (immunoglobulin heavy variable 3-11; interaction score=0.412), and  
89 ENSG00000259680 (uncharacterized protein similar to an immunoglobulin heavy variable 3/OR16 gene;  
90 interaction score=0.412). Among them, *TTR* showed the highest interaction with APP protein (interaction  
91 score=0.936). *BACE2* protein interactive network (Figure 2) showed functional enrichments for several  
92 biological processes and molecular pathways (Table 2). Among the enrichments directly related to  
93 *BACE2* function, we observed: Alzheimer's disease (KEGG hsa05010, FDR  $q = 2.2 \times 10^{-4}$ ) related to the  
94 interaction of *BACE2* with APP and *BACE1*; membrane protein ectodomain proteolysis (GO:0006509,  
95 FDR  $q = 0.007$ ) and amyloid-beta metabolic process (GO:0050435, FDR  $q = 0.007$ ) related to *BACE2*-  
96 *BACE1* interaction; protein metabolic process (GO:0019538, FDR  $q = 0.043$ ) related to the interaction of  
97 *BACE* with APP, *BACE1*, FYN, and IGHV3-11. The interactions of other proteins within *BACE2*  
98 interactive network also highlighted amyloid-related functional enrichments: amyloid fiber formation  
99 (Reactome HSA-977225, FDR  $q = 0.008$ ) and response to amyloid-beta (GO:1904645, FDR  $q = 0.009$ )  
100 related to the interaction of APP with *BACE1* and FYN, respectively.

101 Comparing the epigenetic profile of Val30Met carriers (N=33) vs. that of carriers of other *TTR* mutations  
102 (N=15), we identified a methylation site surviving the epigenome-wide multiple testing correction (Table  
103 1). A CpG site located in the second exon of *TTR* gene (cg13139646) showed a significant  
104 hypomethylation in Val30Met carriers when compared with carriers of other *TTR* mutations (beta= -2.18,  
105  $p=3.34\times 10^{-11}$ , FDR  $q=2.40\times 10^{-5}$ ; Figure 3). To better understand whether the association of Val30Met  
106 with cg13139646 methylation is due to the effect of other regulatory variants in LD with this  
107 amyloidogenic mutation, we conducted a methylation quantitative trait locus (mQTL) analysis in a subset  
108 (N=15) of hATTR patients with complete sequencing of *TTR* coding and non-coding regions. Val30Met  
109 confirmed the strongest association with cg13139646 methylation (beta= -1.07,  $p=0.023$ ; Additional File  
110 1). None of the variants in LD with Val30Met showed stronger evidence of association (Additional File  
111 2). Among the variants tested, Ile68Leu mutation was also associated with cg13139646 methylation:  
112 Ile68Leu carriers are hypermethylated when compared to the carriers of other mutations (beta=1.71,  $p=$   
113  $0.045$ ; Additional File 1). Suggestive evidences of associations were also observed for other *TTR* coding  
114 variants: Ala120Ser (beta=1.62,  $p=0.058$ ) and Gly6Ser (rs1800458, beta=-1.14,  $p=0.069$ ). These coding  
115 variants are not in LD each other (LD  $r^2=0$ ; Additional File 2), indicating each association on cg13139646  
116 methylation is independent. However, non-coding variants located in the upstream and downstream  
117 regions of *TTR* gene showed a perfect LD ( $r^2=1$ ; Additional File 2) with Ile68Leu (LD with upstream  
118 variant rs72922940) and Ala120Ser (LD with downstream variant rs76431866 and upstream variants  
119 ss1360573709 and ss1360573712).

120 Finally, we explored whether the epigenetic changes identified are associated with symptoms reported by  
121 patients affected by hATTR. None of the associations reached a statistical significance (Additional File  
122 3).

123

## 124 **Discussion**

125 hATTR is a rare multi-organ disorder caused by TTR misfolding and consequently amyloid deposition in  
126 several tissues (29). This life-threatening condition is characterized by high clinical heterogeneity with  
127 respect to age of onset, penetrance, and phenotypic manifestation (1-10, 29). Although *TTR*

128 amyloidogenic mutations are the cause of *TTR* misfolding, non-coding variation and modifier genes are  
129 hypothesized to be involved in wide variability of phenotypic manifestations observed in carriers of *TTR*  
130 disease-causing mutations (12, 15, 17-22). Epigenetic modifications (e.g., DNA methylation changes)  
131 could also play an important role in the molecular network regulating the hATTR amyloidogenic process  
132 (25). To explore this hypothesis, we conducted an EWAS investigating more than 700,000 methylation  
133 sites in 48 carriers of *TTR* amyloidogenic mutations and 32 non-carriers. A CpG site (cg09097335)  
134 located in *BACE2* gene was significantly hypomethylated in carriers when compared to non-carriers. This  
135 gene encodes Beta-secretase 2, a protein mainly known for its role in cleaving APP protein in amyloid-  
136 beta, which is a key factor involved in AD pathogenesis (30-32). Several studies showed that, unlike  
137 BACE1 that is the primary  $\beta$ -secretase protein cleaving APP to amyloid-beta, BACE2 is poorly  
138 expressed in the brain and its cleaving ability increases following an inflammatory response (33). APP  
139 processing occurs via three proteolytic cleavages caused by  $\alpha$ -  $\beta$ - and  $\gamma$ -secretase (34). In non-  
140 amyloidogenic processes,  $\alpha$ - and  $\gamma$ -secretases lead to the production of a smaller P3 fragment and APP  
141 intracellular domain, while, in the amyloidogenic pathway,  $\beta$ -secretase and  $\gamma$ -secretase produce amyloid-  
142 beta (34-38). Our results also showed a high-confidence interaction between APP and TTR. Numerous  
143 studies explored the interactions between these two amyloidogenic proteins, displaying a relevant  
144 biological role of TTR in amyloid-beta aggregation and clearance in AD patients (39-43). Specifically,  
145 altered TTR stability seems to reduce the clearance of amyloid-beta, increasing its toxicity in the brain  
146 (39-41). Metal ions and interaction with other proteins could also affect TTR stability (39). Interestingly,  
147 a significant association between amyloid-beta levels and AD was identified in AD patients with *TTR*  
148 Val30Met (39, 43). A putative amyloidogenic role of amyloid-beta in hATTR was also identified in a  
149 post-mortem analysis of a Val30Met carrier where both TTR and amyloid-beta were deposited in the  
150 cerebral leptomeningeal and cortical blood vessel walls with a part of the vessel wall occupied by a  
151 combination of TTR and amyloid-beta aberrant proteins (42). These previous findings strongly indicate  
152 an interplay between the pathogenic mechanisms involved in hATTR and AD. Our epigenome-wide  
153 study identified *BACE2* as a potential key factor in this interaction. As previously discussed, BACE2  
154 protein plays a minor role in APP cleaving in the brain (32, 33), while its activity increases in peripheral

155 tissues under inflammatory response (33). Under this scenario, we hypothesize that the methylation  
156 change observed in the carriers of *TTR* mutations is due to BACE2 response to the inflammation induced  
157 by *TTR* amyloidogenic process in peripheral tissues (44).

158 In the epigenome-wide analysis testing carriers of *TTR* Val30Met vs. carriers of other *TTR* amyloidogenic  
159 mutations, we identified a CpG site, cg13139646, located in the second exon of *TTR* gene. Follow-up  
160 analyses showed that the methylation at this CpG site is independently associated with other *TTR* coding  
161 variants but not by non-coding variants. It is known that methylation profile differs between exonic and  
162 intronic regions (45). Although the transcriptional modulation is strongly regulated by the methylation of  
163 promoter regions, hypomethylation in exonic regions is associated with transcriptional upregulation while  
164 hypermethylation could promote the transcriptional silencing (45, 46). As mentioned, *TTR* amyloid  
165 accumulation causes tissue damage leading to inflammatory response activation, increasing reactive  
166 oxygen species (ROS) production and *TTR* oxidation (47). Val30Met mutation has been associated with  
167 increased S-nitrosylation during the amyloidogenic process, leading to the production of nitric oxide  
168 (NO), which increases the formation of amyloid fibrils (47). The association of Val30Met with these  
169 complex biochemical changes could explain the hypomethylation of cg13139646 in the carriers as a  
170 response to the specific amyloidogenic process induced by this mutation. We could also speculate that  
171 Val30Met and its induced biochemical changes are part of a feedback loop also including methylation  
172 changes and transcriptomic regulation of *TTR* gene. The independent effects observed with respect to  
173 other *TTR* coding variants could be related to the specific amyloidogenic process induced by them. We  
174 also observed suggestive evidence of association between cg13139646 methylation and Gly6Ser, a benign  
175 *TTR* coding variant. However, Levine and Bland (48) further explored the effect of this non-  
176 amyloidogenic mutation in individuals with autonomic and small fiber neuropathy, reporting a potential  
177 role of Gly6ser in the predisposition to neurodegenerative diseases.

178

## 179 **Conclusions**

180 Our study provided novel insights regarding the pathogenesis of hATTR, supporting the involvement of  
181 methylation changes in the amyloidogenic process induced by *TTR* disease-causing mutations. Further

182 studies will be needed to characterize specific mechanisms underlying the epigenetic associations, in  
183 particular, the potential role of amyloid-beta metabolic process and inflammatory response. The  
184 understanding of how methylation changes modulate the penetrance and the severity of *TTR* mutations  
185 could lead to the identification of novel targets to develop treatments and screening tools for the carriers.

186

## 187 **Methods**

188 Thirty-eight symptomatic patients and 10 asymptomatic *TTR* mutations carriers were recruited from three  
189 Italian centers for the treatment of systemic amyloidosis: “San Giovanni Calibita” Fatebenefratelli  
190 Hospital, Isola Tiberina – Rome, Fondazione Policlinico Universitario “A. Gemelli” – Rome and Careggi  
191 University Hospital – Florence (16-20). Thirty-two controls were recruited by the Department of Biology  
192 – University of Rome “Tor Vergata” (Table 3).

193 hATTR diagnosis was based on the presence of clinical signs and symptoms and the presence of an  
194 amyloidogenic mutation on *TTR* gene. The coding mutations identified include: Val30Met (rs28933979),  
195 Phe64Leu (rs121918091), Ile68Leu (rs121918085), Ala120Ser (rs876658108), and Val122Ile  
196 (rs76992529). One hATTR patient is a carrier of a mutation (rs36204272) in an intronic region with a  
197 putative clinical impact (48). Information regarding the organ involvements was collected for each  
198 patient: peripheral and nerve involvement (nerve conduction study); cardiac involvement  
199 (electrocardiographic and echocardiography anomalies); gastrointestinal involvement (gastric paresis,  
200 stypsis, or diarrhea); autonomic neurological involvement (orthostatic hypotension and urinary  
201 incontinence); ocular involvement (vitreous opacities); and carpal tunnel syndrome (median nerve  
202 decompression) (11, 49-51). The present study was approved under the protocol 39/18 by the Comitato  
203 Etico Indipendente, Fondazione Policlinico Tor Vergata – Rome, Italy.

204

## 205 ***DNA methylation analysis***

206 DNA was extracted using the phenol/chloroform protocol (52) and purified through Amicon Ultra-0.5 mL  
207 Centrifugal Filters (EMD Millipore) to achieve a DNA concentration of 100 ng/μL. DNA concentration  
208 was checked via NanoDrop technology (ND-1000, Thermofisher Scientific) and Qubit Quantitation



209 technology (High Accuracy & Sensitivity, Thermofisher). DNA methylation analysis was executed in two  
210 phases: the EZ DNA Methylation kit (Zymo Research) was used to perform sodium bisulfite conversion;  
211 the Illumina Infinium Methylation EPIC Chip (with over 850,000 methylation sites; Illumina Inc.) was  
212 used to quantify DNA methylation according to the standard Illumina protocol. The methylation array  
213 analysis was performed at the Connecting bio-research and Industry Center, Trieste – Italy.

214

### 215 ***Preprocessing, quality control, and normalization***

216 The raw signal intensity files were processed and cleaned using R 3.6 with ChAMP package (53). The  
217 ratio of methylated and unmethylated intensities from idat files was converted into beta values for further  
218 processing. The probes failing thresholds on detection value, bead count, sites near SNPs, probes that  
219 align to multiple positions, sex chromosomes and outliers were removed. None of the samples failed  
220 quality control. The remaining 718,509 probes for 80 individuals were normalized with BMIQ. Batch  
221 effects were assessed using singular vector decomposition and corrected with ComBat method (54). The  
222 genomic lambda of the case-control association was 1.03, calculated using QQPerm package  
223 (<https://cran.r-project.org/web/packages/QQperm/index.html>).

224

### 225 ***Blood cell type composition, genetic variability estimation, and smoking prediction***

226 References-based method was employed to adjust for the heterogeneity due to the cell type composition  
227 of the whole blood samples investigated (55). This method uses specific DNA methylation signatures  
228 derived from purified whole blood cell-type as biomarkers of cell identity, to correct beta value dataset.  
229 Cell proportions for five cell-types (B cells, granulocytes, monocytes, natural killer cells, and T cells)  
230 were detected, and a linear regression was applied (53, 55).

231 To account for the genetic variability among the samples investigated, principal components (PCs) were  
232 calculate using the method proposed by Barfield, Almli (56). This approach allowed us to compute PCs  
233 based on CpGs selected for their proximity to SNPs. The data obtained can be used to adjust for  
234 population stratification in DNA methylation studies when genome-wide SNP data are unavailable (56).

235 Cigarette smoke has a very large effect on DNA methylation profile, triggering alteration at multiple  
236 CpGs (57). Consequently, smoking status needs to be considered as a potential confounder in epigenetic  
237 association studies. EpiSmokEr package was used to classify the smoking status of each participant on the  
238 basis of their epigenetic profile (58). Briefly, EpiSmoker is a prediction tool that provides smoking  
239 probabilities for each individual (never-smoker, former-smoker, and current smoker) using a set of 121  
240 informative CpG sites (57).

241

## 242 ***Data analysis***

243 We conducted two epigenome-wide analyses testing 718,509 methylation sites. First, we investigated the  
244 methylation changes between 48 cases (i.e., carriers of a *TTR* amyloidogenic mutation) and 32 controls.  
245 Second, we analyzed the epigenetic differences between Val30Met carriers (the most frequent mutation in  
246 our cohort; N= 33) and the carriers of other *TTR* mutations (N= 15). In both association analyses, we  
247 implemented a linear regression analysis including cell composition proportions, top three genetic PCs,  
248 epigenetically-determined smoking status, age, and sex as covariates. FDR method was applied to adjust  
249 the results for multiple testing (59) and the q-value < 0.05 was considered as the significance threshold.  
250 STRING v.11.0 (60) was used to identify protein interaction with the loci identified, considering  
251 experiments, co-expression, co-occurrence, gene fusion, and neighborhood as active sources and an  
252 interaction score higher than 0.4 (medium confidence). The protein interaction network was investigated  
253 further conducting functional enrichments association related to the protein-protein interactions identified  
254 considering Gene Ontologies (61) for biological processes and molecular pathways available from  
255 Reactome Database (62) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (63). FDR (q-value <  
256 0.05) was applied to account for multiple testing assuming the whole genome as the statistical  
257 background. To detect associations between genetic variants and methylation changes in sites located in  
258 the chromosomal region of *TTR* gene, we investigated the association of epigenetic changes with genetic  
259 variability of 15 hATTR affected individuals analyzed previously (20). Plink 1.09 (64) was used to  
260 perform association analysis. Haploview (65) was used to determine linkage disequilibrium (LD) among  
261 tested variants.

262

263

## 264 **List of abbreviations**

265 AD, Alzheimer disease; APP, amyloid beta precursor protein; hATTR, Hereditary transthyretin  
266 amyloidosis; BACE1, beta-secretase 1; BACE2, beta-secretase 2; EWAS, epigenome-wide association  
267 studies; FDR, false discovery rate; FYN, FYN proto-oncogene, Src family tyrosine kinase; IGHV3-11,  
268 immunoglobulin heavy variable 3-11; LD, linkage disequilibrium; mQTL, methylation quantitative trait  
269 loci; NO, nitric oxide; ROS, reactive oxygen species; TTR, transthyretin.

270

## 271 **Declarations**

### 272 **Ethics approval and consent to participate**

273 This study was approved under the protocol 39/18 by the Comitato Etico Indipendente, Fondazione  
274 Policlinico Tor Vergata – Rome, Italy. Informed consent was obtained from each participant involved.

275

### 276 **Availability of data and materials**

277 Data supporting the findings of this study are available within this article and its additional files.

278

### 279 **Competing interests**

280 Drs. Fuciarelli and Polimanti received research grants from Pfizer Inc. to conduct epigenetic studies of  
281 hATTR. The other authors reported no biomedical financial interests or potential conflicts of interest.

282

### 283 **Funding**

284 This study was supported by an Investigator-Initiated Research from Pfizer Inc. to the University of  
285 Rome Tor Vergata. Pfizer Inc. had no role in the study design, data analysis, and results interpretation of  
286 the present study.

287

288

289

## 290 **Authors' contributions**

291 ADL, FDA, MF, and RP were involved in study design. MDG, ML, MS, FP, SF, and DM conducted the  
292 recruitment and assessment of the participants. ADL, GAP, and RP carried out the statistical analysis. All  
293 authors were involved in the interpretation of the results. ADL and RP wrote the first draft of the  
294 manuscript and all authors contributed to the final version of the manuscript.

295

## 296 **Acknowledgements**

297 We thank the participants involved in this study and their caregivers.

298

## 299 **Bibliography**

- 300 1. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about  
301 this protein and the design of drugs for TTR amyloidoses? *Curr Med Chem.* 2012;19(15):2324-42.
- 302 2. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. *Transl Neurodegener.*  
303 2014;3:19.
- 304 3. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V.  
305 Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish  
306 population. *Amyloid.* 2008;15(3):181-6.
- 307 4. Conceicao I. Clinical features of TTR-FAP in Portugal. *Amyloid.* 2012;19 Suppl 1:71-2.
- 308 5. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of  
309 transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European  
310 network approach to defining the epidemiology and management patterns for TTR-FAP. *Curr Opin*  
311 *Neurol.* 2016;29 Suppl 1:S3-S13.
- 312 6. Conceicao I, Damy T, Romero M, Galan L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR  
313 amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. *Amyloid.*  
314 2019;26(1):3-9.
- 315 7. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-  
316 related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis.* 2013;8:31.
- 317 8. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic  
318 polyneuropathy (FAP)-type I in Povoia do Varzim and Vila do Conde (north of Portugal). *Am J Med*  
319 *Genet.* 1995;60(6):512-21.
- 320 9. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, et al.  
321 Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.  
322 *J Med Genet.* 2003;40(11):e120.
- 323 10. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic  
324 polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. *Hum Hered.*  
325 1993;43(5):288-94.
- 326 11. Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, et al. TTR-related  
327 amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.  
328 *Neurol Sci.* 2013;34(7):1057-63.

- 329 12. Alves-Ferreira M, Coelho T, Santos D, Sequeiros J, Alonso I, Sousa A, et al. A Trans-acting  
330 Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal. *Mol*  
331 *Neurobiol.* 2018;55(5):3676-83.
- 332 13. Bonaiti B, Olsson M, Hellman U, Suhr O, Bonaiti-Pellie C, Plante-Bordeneuve V. TTR familial  
333 amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin  
334 difference in penetrance? *Eur J Hum Genet.* 2010;18(8):948-52.
- 335 14. Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Mendonca D, Alonso I, et al. Variants in  
336 RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). *Eur J*  
337 *Hum Genet.* 2016;24(5):756-60.
- 338 15. Soares ML, Coelho T, Sousa A, Batalov S, Conceicao I, Sales-Luis ML, et al. Susceptibility and  
339 modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene  
340 disease. *Hum Mol Genet.* 2005;14(4):543-53.
- 341 16. Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto L, Mauro A, et al. Most recent  
342 common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-  
343 phenotype correlation. *Amyloid.* 2015;22(2):73-8.
- 344 17. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the  
345 transthyretin gene among human populations and its correlation with amyloidosis phenotypes. *Amyloid.*  
346 2013;20(4):256-62.
- 347 18. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. In silico analysis of TTR gene (coding  
348 and non-coding regions, and interactive network) and its implications in transthyretin-related  
349 amyloidosis. *Amyloid.* 2014;21(3):154-62.
- 350 19. Iorio A, De Angelis F, Di Girolamo M, Luigetti M, Pradotto LG, Mazzeo A, et al. Population  
351 diversity of the genetically determined TTR expression in human tissues and its implications in TTR  
352 amyloidosis. *BMC Genomics.* 2017;18(1):254.
- 353 20. Iorio A, De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Sabatelli M, et al. Non-coding  
354 variants contribute to the clinical heterogeneity of TTR amyloidosis. *Eur J Hum Genet.* 2017;25(9):1055-  
355 60.
- 356 21. De Lillo A, De Angelis F, Di Girolamo M, Luigetti M, Frusconi S, Manfellotto D, et al. Phenome-  
357 wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the  
358 genetics of hereditary and wildtype transthyretin amyloidoses. *Hum Genet.* 2019;138(11-12):1331-40.
- 359 22. Polimanti R, Nunez YZ, Gelernter J. Increased Risk of Multiple Outpatient Surgeries in African-  
360 American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. *J Clin*  
361 *Med.* 2019;8(2).
- 362 23. Feinberg AP. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. *N Engl J*  
363 *Med.* 2018;378(14):1323-34.
- 364 24. Yan H, Tian S, Slager SL, Sun Z, Ordog T. Genome-Wide Epigenetic Studies in Human Disease:  
365 A Primer on -Omic Technologies. *Am J Epidemiol.* 2016;183(2):96-109.
- 366 25. Szymczak S, Dose J, Torres GG, Heinsen FA, Venkatesh G, Datlinger P, et al. DNA methylation  
367 QTL analysis identifies new regulators of human longevity. *Hum Mol Genet.* 2020.
- 368 26. Clissold RL, Ashfield B, Burrage J, Hannon E, Bingham C, Mill J, et al. Genome-wide  
369 methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion. *Clin*  
370 *Epigenetics.* 2018;10(1):97.
- 371 27. Guay SP, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L. ABCA1 gene promoter  
372 DNA methylation is associated with HDL particle profile and coronary artery disease in familial  
373 hypercholesterolemia. *Epigenetics.* 2012;7(5):464-72.
- 374 28. Magalhaes M, Rivals I, Claustres M, Varilh J, Thomasset M, Bergougnoux A, et al. DNA  
375 methylation at modifier genes of lung disease severity is altered in cystic fibrosis. *Clin Epigenetics.*  
376 2017;9:19.
- 377 29. Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of  
378 Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving  
379 Patient Care. *Ther Clin Risk Manag.* 2020;16:109-23.
- 380 30. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. *Mol*  
381 *Neurodegener.* 2011;6(1):27.


- 382 31. Sassi C, Ridge PG, Nalls MA, Gibbs R, Ding J, Lupton MK, et al. Influence of Coding Variability  
383 in APP-Abeta Metabolism Genes in Sporadic Alzheimer's Disease. *PLoS One*. 2016;11(6):e0150079.
- 384 32. Wang Z, Xu Q, Cai F, Liu X, Wu Y, Song W. BACE2, a conditional beta-secretase, contributes to  
385 Alzheimer's disease pathogenesis. *JCI Insight*. 2019;4(1).
- 386 33. Voytyuk I, Mueller SA, Herber J, Snellinx A, Moechars D, van Loo G, et al. BACE2 distribution  
387 in major brain cell types and identification of novel substrates. *Life Sci Alliance*. 2018;1(1):e201800026.
- 388 34. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. *Mol Brain*.  
389 2011;4:3.
- 390 35. Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, et al. A rare loss-of-function variant of  
391 ADAM17 is associated with late-onset familial Alzheimer disease. *Mol Psychiatry*. 2020;25(3):629-39.
- 392 36. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense  
393 mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. *Neuron*.  
394 2013;80(2):385-401.
- 395 37. Tambini MD, Norris KA, D'Adamio L. Opposite changes in APP processing and human Abeta  
396 levels in rats carrying either a protective or a pathogenic APP mutation. *Elife*. 2020;9.
- 397 38. Durrant CS, Ruscher K, Sheppard O, Coleman MP, Ozen I. Beta secretase 1-dependent amyloid  
398 precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. *Cell*  
399 *Death Dis*. 2020;11(2):98.
- 400 39. Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta  
401 amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease. *CNS Neurosci Ther*.  
402 2017;23(7):605-19.
- 403 40. Costa R, Goncalves A, Saraiva MJ, Cardoso I. Transthyretin binding to A-Beta peptide--impact on  
404 A-Beta fibrillogenesis and toxicity. *FEBS Lett*. 2008;582(6):936-42.
- 405 41. Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin  
406 monomers and tetramers. *Biochemistry*. 2010;49(38):8276-89.
- 407 42. Sakai K, Asakawa M, Takahashi R, Ishida C, Nakamura R, Hamaguchi T, et al. Coexistence of  
408 transthyretin- and Abeta-type cerebral amyloid angiopathy in a patient with hereditary transthyretin  
409 V30M amyloidosis. *J Neurol Sci*. 2017;381:144-6.
- 410 43. Xiang Q, Bi R, Xu M, Zhang DF, Tan L, Zhang C, et al. Rare Genetic Variants of the  
411 Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese. *Mol Neurobiol*.  
412 2017;54(7):5192-200.
- 413 44. Azevedo EP, Guimaraes-Costa AB, Bandeira-Melo C, Chimelli L, Waddington-Cruz M, Saraiva  
414 EM, et al. Inflammatory profiling of patients with familial amyloid polyneuropathy. *BMC Neurol*.  
415 2019;19(1):146.
- 416 45. Chuang TJ, Chen FC, Chen YZ. Position-dependent correlations between DNA methylation and  
417 the evolutionary rates of mammalian coding exons. *Proc Natl Acad Sci U S A*. 2012;109(39):15841-6.
- 418 46. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, et al. DNA methylation of the first  
419 exon is tightly linked to transcriptional silencing. *PLoS One*. 2011;6(1):e14524.
- 420 47. Sharma M, Khan S, Rahman S, Singh LR. The Extracellular Protein, Transthyretin Is an Oxidative  
421 Stress Biomarker. *Front Physiol*. 2019;10:5.
- 422 48. Levine TD, Bland RJ. Incidence of nonamyloidogenic mutations in the transthyretin gene in  
423 patients with autonomic and small fiber neuropathy. *Muscle Nerve*. 2018;57(1):140-2.
- 424 49. Russo M, Mazzeo A, Stancanelli C, Di Leo R, Gentile L, Di Bella G, et al. Transthyretin-related  
425 familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late  
426 onset. *J Peripher Nerv Syst*. 2012;17(4):385-90.
- 427 50. Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, et al. Transthyretin-Related  
428 Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic  
429 Area. *J Neuromuscul Dis*. 2015;2(s2):S39-S48.
- 430 51. Gagliardi C, Perfetto F, Lorenzini M, Ferlini A, Salvi F, Milandri A, et al. Phenotypic profile of  
431 Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. *Eur J Heart Fail*.  
432 2018;20(10):1417-25.
- 433 52. Budowle B, Moretti, T., Smith, J., and Dizinno, J. DNA typing protocols: Molecular Biology and  
434 Forensic analysis. A Bio Techniques® Books Publications (Natick, MA: Eaton Publishing). 2000.

- 435 53. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation  
436 analysis pipeline for Illumina BeadChips. *Bioinformatics*. 2017;33(24):3982-4.
- 437 54. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using  
438 empirical Bayes methods. *Biostatistics*. 2007;8(1):118-27.
- 439 55. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al.  
440 DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*.  
441 2012;13:86.
- 442 56. Barfield RT, Almlı LM, Kilaru V, Smith AK, Mercer KB, Duncan R, et al. Accounting for  
443 population stratification in DNA methylation studies. *Genet Epidemiol*. 2014;38(3):231-41.
- 444 57. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking  
445 leads to extensive genome-wide changes in DNA methylation. *PLoS One*. 2013;8(5):e63812.
- 446 58. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to  
447 determine smoking status from DNA methylation data. *Epigenomics*. 2019;11(13):1469-86.
- 448 59. Benjamini Y, Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful  
449 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*.  
450 1995;57:289-300.
- 451 60. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:  
452 protein-protein association networks with increased coverage, supporting functional discovery in genome-  
453 wide experimental datasets. *Nucleic Acids Res*. 2019;47(D1):D607-D13.
- 454 61. The Gene Ontology C. The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic  
455 Acids Res*. 2019;47(D1):D330-D8.
- 456 62. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway  
457 knowledgebase. *Nucleic Acids Res*. 2020;48(D1):D498-D503.
- 458 63. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on  
459 genomes, pathways, diseases and drugs. *Nucleic Acids Res*. 2017;45(D1):D353-D61.
- 460 64. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:  
461 rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7.
- 462 65. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype  
463 maps. *Bioinformatics*. 2005;21(2):263-5.

464

465

466



467

468

469 **Figure 1:** Methylation levels of cg09097696 site in carriers vs. non-carriers of amyloidogenic mutations.

470

471


472

473



474

475



476


477 **Figure 2:** BACE2 protein interaction network. Node colour of the protein is proportional to the  
478 interaction score with BACE2. Connector shade and width are proportional to the interaction confidence  
479 (highest, high, and medium).

480

481

482

483



484

485 **Figure 3:** Methylation levels of cg13139646 site in Val30Met carriers vs. carriers of other TTR

486 amyloidogenic mutations.

487

488

489

490

.91 **Table 1:** Significant methylation sites identified in the case-control analysis and in the Val30Met analysis. Information about cg probe (cgID), chromosome  
 .92 localization (chr), position (pos), CpG context, mapped gene, gene region, effect (beta), p value (p-value) and false discovery rate (FDR) q value are  
 .93 reported.  
 .94  
 .95

cgID	chr	pos	CpG context	Mapped gene	Gene region	beta	p-value	FDR
<b>Cases vs Controls</b>								
<b>cg09097335</b>	21	42597642	Open Sea	<i>BACE2</i>	Body	-0.60	6.26×10 <sup>-8</sup>	0.044
<b>Val30Met vs non-Val30Met</b>								
<b>cg13139646</b>	18	29172936	Open Sea	<i>TTR</i>	Body	-2.18	2.14×10 <sup>-7</sup>	7.86×10 <sup>-5</sup>

i10

i11

**Table 2:** Enrichments for gene ontologies (GO) of biological processes and for Reactome and KEGG molecular pathways (HSA and hsa, respectively).

<b>ID</b>	<b>Description</b>	<b>Proteins</b>	<b>False Discovery Rate</b>
<b>hsa05010</b>	Alzheimer's disease	APP,BACE1,BACE2	2.2E-04
<b>HSA-2029481</b>	FCGR activation	FYN,IGHV3-11	7.9E-04
<b>HSA-2730905</b>	Role of LAT2/NTAL/LAB on calcium mobilization	FYN,IGHV3-11	7.9E-04
<b>HSA-983695</b>	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	FYN,IGHV3-11	0.002
<b>GO:0006509</b>	membrane protein ectodomain proteolysis	BACE1,BACE2	0.007
<b>GO:0050435</b>	amyloid-beta metabolic process	BACE1,BACE2	0.007
<b>GO:1902950</b>	regulation of dendritic spine maintenance	APP,FYN	0.007
<b>HSA-977225</b>	Amyloid fiber formation	APP,BACE1	0.008
<b>GO:1904645</b>	response to amyloid-beta	APP,FYN	0.009
<b>HSA-109582</b>	Hemostasis	APP,FYN,IGHV3-11	0.010
<b>GO:0106027</b>	neuron projection organization	APP,FYN	0.010
<b>GO:1900449</b>	regulation of glutamate receptor signaling pathway	APP,FYN	0.010
<b>HSA-202733</b>	Cell surface interactions at the vascular wall	FYN,IGHV3-11	0.010
<b>GO:0061098</b>	positive regulation of protein tyrosine kinase activity	APP,FYN	0.017
<b>GO:1903201</b>	regulation of oxidative stress-induced cell death	APP,FYN	0.017
<b>GO:0006897</b>	Endocytosis	APP,FYN,IGHV3-11	0.018
<b>GO:0007631</b>	feeding behavior	APP,FYN	0.018
<b>GO:0016358</b>	dendrite development	APP,FYN	0.018
<b>GO:0038096</b>	Fc-gamma receptor signaling pathway involved in phagocytosis	FYN,IGHV3-11	0.018
<b>GO:1901216</b>	positive regulation of neuron death	APP,FYN	0.018
<b>GO:1903426</b>	regulation of reactive oxygen species biosynthetic process	APP,FYN	0.018
<b>GO:1900180</b>	regulation of protein localization to nucleus	APP,FYN	0.020
<b>GO:0007612</b>	Learning	APP,FYN	0.027
<b>GO:0031347</b>	regulation of defense response	APP,FYN,IGHV3-11	0.027
<b>GO:2001056</b>	positive regulation of cysteine-type endopeptidase activity	APP,FYN	0.027
<b>GO:0030162</b>	regulation of proteolysis	APP,FYN,IGHV3-11	0.031
<b>GO:0051897</b>	positive regulation of protein kinase B signaling	APP,FYN	0.031
<b>GO:2000377</b>	regulation of reactive oxygen species metabolic process	APP,FYN	0.031

<b>HSA-168249</b>	Innate Immune System	APP,FYN,IGHV3-11	0.032
<b>HSA-76002</b>	Platelet activation, signaling and aggregation	APP,FYN	0.032
<b>GO:0050808</b>	synapse organization	APP,FYN	0.034
<b>GO:1901215</b>	negative regulation of neuron death	APP,FYN	0.034
<b>GO:0002684</b>	positive regulation of immune system process	APP,FYN,IGHV3-11	0.037
<b>GO:0050776</b>	regulation of immune response	APP,FYN,IGHV3-11	0.037
<b>GO:0002252</b>	immune effector process	APP,FYN,IGHV3-11	0.041
<b>GO:0007411</b>	axon guidance	APP,FYN	0.041
<b>GO:0019538</b>	protein metabolic process	APP,BACE1,BACE2,FYN,IGHV3-11	0.043
<b>GO:0006959</b>	humoral immune response	APP,IGHV3-11	0.045

i12

i13

i14

i15

i16

i17

i18

i19

i20

i21

i22

i23

i24

i25 **Table 3:** Description of the study population. Information about *TTR* amyloidogenic mutations, sex, age, epigenetically-determined smoking status (never  
i26 smoker, NS; former smoker, FS; current smoker, CS), and epigenetically-estimated ranges of T cells (CD8T and CD4T), Natural Killer cells (NK), B cells,  
i27 monocytes (Mono) and granulocytes (Gran) are reported.

i28

<i>TTR</i> Mutation	<i>N</i>	<i>Sex</i> Female (%)	<i>Age Median</i> (Min-Max)	<i>Smoking</i>			<i>CD8T Median</i> (Min –Max)	<i>CD4T Median</i> (Min –Max)	<i>NK Median</i> (Min –Max)	<i>B cell Median</i> (Min –Max)	<i>Mono Median</i> (Min –Max)	<i>Gran Median</i> (Min –Max)
				<i>NS</i>	<i>FS</i>	<i>CS</i>						
<b>Cases</b>												
Val30Met	33	10 (30)	65 (31-88)	1	23	9	0.033 (-3.24×10 <sup>-20</sup> – 0.131)	0.118 (1.1×10 <sup>-2</sup> – 0.21)	0.033 (-3.81×10 <sup>-19</sup> – 0.127)	1.52×10 <sup>-3</sup> (-5.55×10 <sup>-19</sup> – 0.066)	0.082 (0.038 – 0.147)	0.634 (0.551 – 0.824)
Phe64Leu	8	1 (12)	70 (48-75)	0	4	4	4.02×10 <sup>-3</sup> (1.07×10 <sup>-18</sup> – 1.112)	0.127 (6.9×10 <sup>-2</sup> – 0.228)	0.014 (1.96×10 <sup>-20</sup> – 0.099)	3.13×10 <sup>-3</sup> (-2.17×10 <sup>-19</sup> – 0.021)	0.085 (0.057 – 0.107)	0.65 (0.46 – 0.70)
Ala120Ser	2	2 (100)	67-68	0	2	0	-3.34×10 <sup>-20</sup> – 0	0.068 – 0.11	8.1×10 <sup>-3</sup> – 1.28×10 <sup>-1</sup>	0 – 5.1×10 <sup>-3</sup>	0.092 – 0.11	0.56 – 0.74
Ile68Leu	3	0	53 (30-62)	0	0	3	0	0.142 (0.07 – 0.16)	0.038 (0.013 – 0.041)	4.4×10 <sup>-3</sup> (3.8×10 <sup>-3</sup> – 5.1×10 <sup>-3</sup> )	0.083 (0.096 – 0.147)	0.59 (0.603 – 0.70)
Val122Ile	1	0	80	0	0	1	0	0.23	0.042	0.005	0.071	0.55
rs36204272*	1	0	65	0	1	0	0.069	0.14	0.052	0.006	0.129	0.505
<b>Controls</b>												
–	32	19 (59)	37 (20-76)	0	27	5	0.015 (8.45×10 <sup>-19</sup> – 0.13)	0.16 (0.045 – 0.34)	0.044 (-2.68×10 <sup>-19</sup> – 0.18)	0.014 (1.08×10 <sup>-19</sup> – 0.091)	0.092 (0.051 – 0.13)	0.571 (0.41 – 0.74)

i29 \*non-coding variant of uncertain clinical impact

i30